EMCURE PHARMACEUTICALS
|
The Current P/E Ratio of EMCURE PHARMACEUTICALS is 40.73.
| Share Price | ₹2,345.9 | Nov 19,2026 |
| Market Cap | ₹44,501.7 Cr | |
| Earnings-TTM | ₹1,092.7 Cr | TTM-Consolidated Results |
| Price/Earnings | 40.73x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of EMCURE PHARMACEUTICALS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹44,501.7 Cr] as on Nov 19,2026
(/) Earnings [ ₹1,092.7 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 40.73x ]
Thus, for EMCURE PHARMACEUTICALS , the investors are currently willing to pay 40.73 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of EMCURE PHARMACEUTICALS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of EMCURE PHARMACEUTICALS over the last five years.
Historical PE (Price/Earnings) ratio chart of EMCURE PHARMACEUTICALS
PE Ratio Performance Analysis for EMCURE PHARMACEUTICALS
- EMCURE PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 12.51x.
- EMCURE PHARMACEUTICALS 's operated at median p/e ratio of 0x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, EMCURE PHARMACEUTICALS 's p/e ratio peaked in Mar2026 at 32.73x.
- EMCURE PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2024 of 0x.
How does EMCURE PHARMACEUTICALS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| EMCURE PHARMACEUTICALS | 1,092.67 | 40.73 | 44,501.7 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,037.20 | 40.70 | 449,228.0 |
| DIVIS LABORATORIES LTD | 3,363.00 | 88.24 | 296,741.0 |
| TORRENT PHARMACEUTICALS LTD | 2,099.00 | 84.05 | 176,413.0 |
| CIPLA LTD | 2,868.29 | 39.88 | 114,397.0 |
| DR REDDYS LABORATORIES LTD | 2,759.70 | 42.31 | 116,771.0 |
| MANKIND PHARMA LTD | 2,249.69 | 48.47 | 109,040.0 |
| LUPIN LTD | 5,221.47 | 17.51 | 91,412.9 |
| ZYDUS LIFESCIENCES LTD | 4,159.00 | 28.66 | 119,202.0 |
| AUROBINDO PHARMA LTD | 3,993.05 | 26.04 | 103,971.0 |
| LAURUS LABS LTD | 1,333.75 | 93.26 | 124,380.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs EMCURE PHARMACEUTICALS 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 17.51x |
| Max industry PE | 93.26x |
| Median industry PE | 40.73x |
| Average industry PE | 49.99x |
You may also like the below Video Courses